Exhibit 32.1
CERTIFICATIONS OF PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER
PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of Tarsus Pharmaceuticals, Inc. (the “Company”) on Form 10-Q for the period ended September 30, 2021 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Bobak Azamian, hereby certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:
| | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | |
| (1) | The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and |
| | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | |
| (2) | The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company. |
| | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | |
| Date: November 10, 2021 | By: | /s/ Bobak Azamian, M.D., Ph.D. |
| | Bobak Azamian, M.D., Ph.D. |
| | President and Chief Executive Officer |
| | (Principal Executive Officer) |
